Top Markets
#1 Black Phoenix Black Phoenix +3,787.95%
#2 Nesa Nesa +758.35%
#3 Ontology Gas Ontology Gas +154.35%
#4 ADO Protocol ADO Protocol +104.16%
#5 Cortex Cortex +95.89%
#6 Kinesis Silver Kinesis Silver +54.48%
#7 Non-Playable Coin Non-Playable Coin +34.27%
#8 Pons Pons +32.57%
#9 Ontology Ontology +31.01%
#10 Cash Cat Cash Cat +30.78%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
UniQure N.V. UniQure N.V.

UniQure N.V.

QURE
Classement en actions #4587
uniQure N.V. develops treatments for patients suffering from rare and other... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Prix de l'action
$50.67
Capitalisation boursière
$3.51B
Changement (1 jour)
-0.75%
Changement (1 an)
220.87%
Pays
NL
Échange UniQure N.V. (QURE)

Catégorie

Healthcare
Revenus pour UniQure N.V. (QURE)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de UniQure N.V., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour UniQure N.V. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH